Last month, the U.S. Food and Drug Administration approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adults with malignant pleural mesothelioma that cannot be removed by surgery. This is the first drug regimen approved for mesothelioma in 16 years and the second FDA-approved systemic therapy for mesothelioma.
Said the FDA in a press release: “Today’s approval of nivolumab plus ipilimumab provides a new treatment that has demonstrated an improvement in overall survival for patients with malignant pleural mesothelioma,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Oncologic Diseases in the FDA’s Center for Drug Evaluation and Research. “In 2004, FDA approved pemetrexed in combination with cisplatin for this indication, and now patients now have an important, additional treatment option after more than a decade with only one FDA-approved drug regimen.”
Read the article.
Nass Cancelliere has established itself as one of the premier asbestos law firms and jury trial lawyers in the country. Our firm strongly believes that if an asbestos defendant does not offer our client fair compensation for their disease, then they should be taken to Court. Over the past 40 years, we have obtained millions of dollars in asbestos jury verdicts for our clients. View our settlements and verdicts.
If you or a loved one has been exposed to asbestos, contact our law office today by completing the Contact Us form on this website or by selecting the Live Chat button on any website page. You can also reach Nass Cancelliere by phone toll free at 215-546-8200, or by calling your local Nass Cancelliere office directly.